Navigation Links
Innocoll Announces Closing of $30 Million Equity Financing Investment
Date:12/17/2007

ASHBURN, Va., Dec. 17 /PRNewswire-FirstCall/ -- Innocoll, Inc., a privately held specialty pharmaceutical company, announced that it has closed an equity financing investment to raise $30 million through the sale of convertible preferred stock in a private placement with three institutional investors led by Camulos Capital LP together with NewSmith Asset Management LLP and Morgan Stanley & Co, Incorporated. The existing principal shareholders, Rolf and William Schmidt, also converted existing loans totaling approximately $16 million into convertible preferred stock. The financing will be used to fund a series of phase 2 and phase 3 clinical trials for Innocoll's lead product development programs, payment of financing fees, and general corporate purposes.

Commenting on the equity financing, Dr. Michael Myers, President and CEO said, "We are delighted to have attracted three institutional investors of the caliber of Camulos, NewSmith and Morgan Stanley to make a significant financial investment in our business. In 2007, we have seen the approval of three INDs for products which are now in active clinical development and, according to market research performed by L.E.K. Consulting, have combined annual sales projections of approximately $800 million in the U.S. alone. Having secured the necessary funding, we are well placed to move forward aggressively with the clinical development of our lead pharmaceutical products."

Mr. Rolf Schmidt, Chairman of Innocoll's Board of Directors at the time of the transaction added "We are excited to be working with a group of highly knowledgeable investors who bring many years of healthcare industry experience and can ably assist us in the development and commercialization of our pipeline of innovative products."

"This investment is an opportunity to finance the U.S. development of several late stage products that have proven efficacy and safety in Europe. We look forward to working with Dr. Myers and his team on the product portfolio, which has both compelling therapeutic benefits and strong commercial potential" said Courtney Carson, an analyst at Camulos Capital LP and a newly appointed Director of Innocoll, Inc.

NewSmith Financial Products LLP and Sudbrook Associates LLP acted as financial advisor to Innocoll in this transaction.

About Innocoll, Inc.

Innocoll is a privately held, specialty pharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). The Company is internationally-based with Corporate Headquarters in the United States, Research & Development and Product Commercialization Divisions in Ireland, and manufacturing facilities in Germany and South Africa.

Innocoll's lead product, GENTAMICIN SURGICAL IMPLANT, is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It was developed using Innocoll's proprietary collagen-based drug delivery technology, CollaRx, and is designed to provide a high localized concentrations of gentamicin at the target tissue. The product is indicated as an adjunct to systemic antibiotic therapy for the prevention of surgical site infections and for the treatment of deep, localized infections in both hard and soft tissues. There are more than 60 prospective clinical trials and published case reports totaling over 7,500 patients documenting safety and efficacy over a broad range of orthopedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures. The product is already approved for sale in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In 2005, Innocoll acquired the worldwide marketing rights from Essex Chemis AG, an affiliated company of Schering Plough Corporation (NYSE: SGP) and in August 2007 sold its marketing rights, with the exception of the U.S., to EUSA Pharma. GENTAMICIN SURGICAL IMPLANT is currently in phase 3 clinical development in the U.S. for the prevention of surgical site infections. Innocoll will conduct two US multi- centered phase 3 clinical trials; one in cardiac surgery patients at higher risk of surgical site infection and the other in patients undergoing open colorectal surgery. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the Study Co-ordinating Center for both trials. Independent market research recently performed by L.E.K. Consulting has projected peak U.S. sales of GENTAMICIN SURGICAL IMPLANT at more than $200 million per annum.

Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx GENTAMICIN TOPICAL for the treatment and prevention of infected diabetic foot ulcers and CollaRx BUPIVACAINE IMPLANT for the management of post-operative pain, which are both in Phase 2 clinical trials.

CollaRx GENTAMICIN TOPICAL represents the clinical development of the marketed GENTAMICIN SURGICAL IMPLANT for the topical treatment and prevention of infection in chronic skin ulcers, such as diabetic foot. A high proportion of chronic wounds become clinically infected requiring treatment with antibiotics. Orally administered and injected antibiotics are often associated with systemic side effects and widespread use can lead to development of bacterial resistance. Furthermore, diabetic ulcers are often associated with vascular disease and restricted peripheral blood flow (ischemia), which may render systemically acting antibiotics less effective. Innocoll plans to investigate CollaRx GENTAMICIN TOPICAL for the localized treatment and prevention of diabetic foot infections in patients with moderately infected, mildly infected and uninfected ulcers in a parallel series of three phase 2 multi-centered clinical trials. Currently, there are no topically applied antibiotics marketed in the U.S. that are specifically indicated for the treatment of infected diabetic foot ulcers and recent market research independently performed by L.E.K. Consulting forecast peak annual revenues approaching $270 million for the diabetic foot indication in the U.S. alone.

BUPIVACAINE SURGICAL IMPLANT has been specifically developed and formulated using Innocoll's proprietary CollaRx sponge technology for the management of post-operative pain following moderate/major abdominal, gynecological, thoracic, and orthopedic surgeries. Post-operative pain is typically controlled with narcotic analgesics such as morphine, but systemic administration of these drugs can result in unfavorable side effects including suppression of breathing, sedation, nausea and vomiting; and can also affect patient recovery. BUPIVACAINE SURGICAL IMPLANT is designed to provide pain control directly at the surgical site and thus reduce the level of additional analgesia required following surgery. The collagen matrix naturally biodegrades over a few days and the bupivacaine is released to provide local analgesia for up to 96 hours post-operatively, as demonstrated by the results of an initial clinical study performed at Wexham Park Hospital, Slough, UK, in patients undergoing hysterectomy surgery. Starting later this month, Innocoll plans to conduct a series of phase 2, multi-centered, controlled clinical trials in various soft tissue and orthopedic surgeries. The product is believed to have broad utility spanning a wide variety of surgical procedures and independent market research recently performed by L.E.K. Consulting has projected peak U.S. sales nearing $310 million

For more information about Innocoll, its technologies and products, please visit http://www.innocoll.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):